Shire human Genetic Therapies

Shire Human Genetic Therapies (HGT) was the specialized rare disease division of Shire PLC, dedicated to developing and commercializing therapies for orphan conditions. The division was established following the acquisition of Transkaryotic Therapies in 2005 and became a global leader in the treatment of lysosomal storage disorders. Its portfolio included blockbuster enzyme replacement therapies such as Elaprase for Hunter syndrome and Replagal for Fabry disease, as well as treatments for hereditary angioedema. Based in Lexington, Massachusetts, HGT served as the primary innovation engine for Shire's high-growth rare disease business. In 2019, the entire Shire organization was acquired by Takeda Pharmaceutical Company for approximately $62 billion, integrating HGT's assets into Takeda's Rare Disease unit.